Cadila Healthcare: Take care - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cadila Healthcare: Take care

May 3, 2001

Cadila Healthcare Ltd. results are below our expectations. Though, year on year basis sales have grown by 6.5% (expected 10.5%), it has infact showed a negative growth (2.7%) on a sequential basis. Operating margins have dipped from 18% in Q3FY01 to a paltry 5.9% in Q4FY01. The sudden drop in operating margins is unexplained at this point of time. Thanks to substantial reduction in interest cost and income from parking of IPO funds, bottomline showed an apparent growth of 64%.

(Rs m) FY00 FY01 Change 3QFY01 4QFY01 Growth**
Sales 4,778 5,088 6.5% 1171 1139 -2.7%
Other Income 74 74 0.0% 25 -8 -132.0%
Expenditure 4,088 4,351 6.4% 960 1072 11.7%
Operating Profit (EBDIT) 690 737 6.8% 211 67 -68.2%
Operating Profit Margin (%) 14.4% 14.5% 0.3% 18.0% 5.9% -67.4%
Interest 213 (46) -121.6% 0 (57) -
Depreciation 99 149 50.5% 44 24 -45.5%
Profit before Tax 452 708 56.6% 192 92 -52.1%
Tax 53 55 3.8% 18 11 -38.9%
Profit after Tax/(Loss) 399 653 63.7% 174 81 -53.4%
Net profit margin (%) 8.4% 12.8% 14.9% 7.1%
No. of Shares (eoy) (m) 60 60 60 60
Diluted Earnings per share* 6.7 10.9 11.6 5.4
P/E (at current price) 15.1 9.3
(*- annualised)
**- Sequential Growth

In a related development , the company recently acquired a 27.7% stake in German Remedies at a cost of Rs 1.49 bn. The acquisition was effectively valued at 2.4 times German Remedies sales. It also acquired perpetual rights to market five leading brands from Asta (one of the promoter of German Remedies). The financing of the same would be done through a mix of debt (Rs 2,000 m) and internal accruals. The company expects to leverage this acquisition to enter high margin therapeutic segments like respiratory, gynaecology and oncology, where German Remedies has a strong presence.

Particulars Cadila Sun Pharma Cipla
CMP (Rs.) 101 550 1,127
Sales (In Rs. Mn) 5,088 6,132 10,477
Growth (YoY) 6.5% 28.1% 38.0%
Operating Profit Margins 14.5% 24.6% 20.6%
P/e (FY 2001) (x) 9.3 19 38
Market Capitalisation (In Rs Mn) 6,060 24,853 67,577
Market Cap/Sales (x) 1.2 4.1 6.5

At the current market price of Rs 101, the stock is valued at 9.3 times its FY01 earnings and 1.2 times its current market capitalisation to sales. The prospects of the company would depend on how fast the ambitious acquisitions pays off. The company also needs to gear up growth, particularly given the fact that its peers like Sun Pharma are growing at much faster rates.

Equitymaster requests your view! Post a comment on "Cadila Healthcare: Take care". Click here!


More Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY22); Net Profit Up 35.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 35.0% YoY). Sales on the other hand came in at Rs 40 bn (up 14.5% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2020-21 Annual Report Analysis (Annual Result Update)

Aug 10, 2021 | Updated on Aug 10, 2021

Here's an analysis of the annual report of CADILA HEALTHCARE for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Cadila Healthcare Reports 73% Rise in Profits (Views On News)

May 28, 2021

A look into the company's quarter four financial performance.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 7, 2021 02:31 PM


  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks